EUVIMEDEUVIMED entdecken
Leserbrief

Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice

Rubén García Castro, Araceli Sánchez Gilo, Pablo Chicharro Manso

Dermatitis® · 01.11.2026 · 37 (6)

DOI: 10.1177/17103568261421387 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Dermatitis®, online erschienen am 20.03.2026. Verfasst von Rubén García Castro und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain. Die Arbeit nennt 5 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain.

Zitieren

APA

García Castro, R., Sánchez Gilo, A., & Chicharro Manso, P. (2026). Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice. Dermatitis®, 37(6). https://doi.org/10.1177/17103568261421387

Vancouver

García Castro R, Sánchez Gilo A, Chicharro Manso P. Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice. Dermatitis®. 2026;37(6). doi:10.1177/17103568261421387

BibTeX
@article{GarcaCastro2026,
  author = {García Castro, Rubén and Sánchez Gilo, Araceli and Chicharro Manso, Pablo},
  title = {Letter: Short-Term Effectiveness and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis in Real-World Clinical Practice},
  journal = {Dermatitis®},
  year = {2026},
  volume = {37},
  number = {6},
  doi = {10.1177/17103568261421387}
}
Kostenlos starten →